Septerna (NASDAQ:SEPN) Trading Up 8.4% – Still a Buy?

Shares of Septerna, Inc. (NASDAQ:SEPN) shot up 8.4% on Monday . The stock traded as high as $26.43 and last traded at $26.31. 52,213 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 337,603 shares. The stock had previously closed at $24.28.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SEPN shares. TD Cowen initiated coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price for the company. Finally, Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock.

Septerna Stock Performance

The business’s 50-day moving average is $23.66.

Insider Transactions at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.